MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
暂无分享,去创建一个
B. Quesnel | E. Bertrand | C. Preudhomme | C. Maurage | X. Leleu | B. Hivert | C. Roumier | F. Morschhauser | P. Duthilleul | E. Boyle | S. Poulain | C. Herbaux | S. Geffroy | M. Wémeau | L. Terriou | H. Demarquette | J. Pollet | B. Onraed | A. Verrier
[1] A. Roccaro,et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. , 2014, Blood.
[2] S. Treon,et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.
[3] J. Miguel,et al. LYMPHOID NEOPLASIA C 1013 G / CXCR 4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma , 2014 .
[4] B. Quesnel,et al. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia , 2013, American journal of hematology.
[5] B. Barlogie,et al. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. , 2013, Clinical lymphoma, myeloma & leukemia.
[6] M. Cazzola,et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. , 2013, Blood.
[7] N. Munshi,et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.
[8] L. del Vecchio,et al. Diagnostic strategies to investigate cerebrospinal fluid involvement in haematological malignancies. , 2013, Leukemia research.
[9] N. Gutiérrez,et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia , 2013, Leukemia.
[10] B. Quesnel,et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. , 2012, Blood.
[11] I. Ghobrial. Are you sure this is Waldenstrom macroglobulinemia? , 2012, Hematology. American Society of Hematology. Education Program.
[12] R. Siebert,et al. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma , 2012, Acta Neuropathologica.
[13] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.
[14] K. Hoang-Xuan,et al. Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.
[15] G. Schulte-Altedorneburg,et al. Current strategies in the diagnosis of diffuse large B‐cell lymphoma of the central nervous system , 2012, British journal of haematology.
[16] R. Siebert,et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma , 2011, Acta Neuropathologica.
[17] K. Horikawa,et al. Oncogenic MYD88 mutation drives Toll pathway to lymphoma , 2011, Immunology and cell biology.
[18] P. Schaefer,et al. Novel diagnostic approaches in Bing-Neel syndrome. , 2011, Clinical lymphoma, myeloma & leukemia.
[19] H. Zetterberg. Pathognomonic cerebrospinal fluid findings in Bing–Neel syndrome , 2011, Journal of Neuro-Oncology.
[20] J. Raizer,et al. Bing–Neel syndrome: an illustrative case and a comprehensive review of the published literature , 2010, Journal of Neuro-Oncology.
[21] J. Bing,et al. Two Cases of Hyperglobulinaemia with Affection of the Central Nervous System on a Toxi‐Infectious Basis.1 , 2009 .
[22] B. Guidet,et al. ‘Indolent’ Waldenstrom's macroglobulinemia and a cerebrospinal fluid protein level of 16 g/L , 2006, European journal of haematology.
[23] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.